Movement Alert｜RemeGen Rises 5.02% in Regular Trading, Sector Rebounds as Lock-up Expiry Selling Pressure Eased by Regulatory Restriction

Market Focus06-23

On June 23, RemeGen rose 5.02% in regular trading, trading at HKD 68.3/share, with turnover of HKD 117 million.

On the news front, the Hong Kong biotech sector staged a collective rebound following a sharp selloff in the prior session. Peers including CStone Pharmaceuticals and康诺亚 rose 7%, Akeso gained 4.28%, and Innovent Biologics added 3.19%, signaling a clear recovery in sector sentiment. On June 22, the broader sector had been under sustained selling pressure due to concerns over Fed rate hike expectations and BD licensing uncertainties.

Additionally, RemeGen announced on June 22 that 193 million first-offering restricted shares, representing 34.16% of total share capital, will become tradeable on July 1. However, because the company has not met cash dividend distribution requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing their A-share holdings via centralized bidding or block trading. This regulatory restriction substantially mitigates actual selling pressure expectations, alleviating market concerns over the lock-up expiry impact.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104046817?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104046817","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Rises 5.02% in Regular Trading, Sector Rebounds as Lock-up Expiry Selling Pressure Eased by Regulatory Restriction","media":"Market Focus","content":"<p><p>On June 23, RemeGen rose 5.02% in regular trading, trading at HKD 68.3/share, with turnover of HKD 117 million.</p><p>On the news front, the Hong Kong biotech sector staged a collective rebound following a sharp selloff in the prior session. Peers including CStone Pharmaceuticals and康诺亚 rose 7%, Akeso gained 4.28%, and Innovent Biologics added 3.19%, signaling a clear recovery in sector sentiment. On June 22, the broader sector had been under sustained selling pressure due to concerns over Fed rate hike expectations and BD licensing uncertainties.</p><p>Additionally, RemeGen announced on June 22 that 193 million first-offering restricted shares, representing 34.16% of total share capital, will become tradeable on July 1. However, because the company has not met cash dividend distribution requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing their A-share holdings via centralized bidding or block trading. This regulatory restriction substantially mitigates actual selling pressure expectations, alleviating market concerns over the lock-up expiry impact.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Rises 5.02% in Regular Trading, Sector Rebounds as Lock-up Expiry Selling Pressure Eased by Regulatory Restriction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Rises 5.02% in Regular Trading, Sector Rebounds as Lock-up Expiry Selling Pressure Eased by Regulatory Restriction\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, RemeGen rose 5.02% in regular trading, trading at HKD 68.3/share, with turnover of HKD 117 million.</p><p>On the news front, the Hong Kong biotech sector staged a collective rebound following a sharp selloff in the prior session. Peers including CStone Pharmaceuticals and康诺亚 rose 7%, Akeso gained 4.28%, and Innovent Biologics added 3.19%, signaling a clear recovery in sector sentiment. On June 22, the broader sector had been under sustained selling pressure due to concerns over Fed rate hike expectations and BD licensing uncertainties.</p><p>Additionally, RemeGen announced on June 22 that 193 million first-offering restricted shares, representing 34.16% of total share capital, will become tradeable on July 1. However, because the company has not met cash dividend distribution requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing their A-share holdings via centralized bidding or block trading. This regulatory restriction substantially mitigates actual selling pressure expectations, alleviating market concerns over the lock-up expiry impact.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1104046817","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104046817","pubTimestamp":1782180217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, RemeGen rose 5.02% in regular trading, trading at HKD 68.3/share, with turnover of HKD 117 million.On the news front, the Hong Kong biotech sector staged a collective rebound following a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"动向提示|RemeGen常规交易涨5.02%监管限制缓解禁售到期抛压板块反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On June 23, RemeGen rose 5.02% in regular trading, trading at HKD 68.3/share, with turnover of HKD 117 million.On the news front, the Hong Kong biotech sector staged a collective rebound following a sharp selloff in the prior session. Peers including CStone Pharmaceuticals and康诺亚 rose 7%, Akeso gained 4.28%, and Innovent Biologics added 3.19%, signaling a clear recovery in sector sentiment. On June 22, the broader sector had been under sustained selling pressure due to concerns over Fed rate hike expectations and BD licensing uncertainties.Additionally, RemeGen announced on June 22 that 193 million first-offering restricted shares, representing 34.16% of total share capital, will become tradeable on July 1. However, because the company has not met cash dividend distribution requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing their A-share holdings via centralized bidding or block trading. This regulatory restriction substantially mitigates actual selling pressure expectations, alleviating market concerns over the lock-up expiry impact.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104046817","isCrawlerRequest":true}